Zura Bio to Present at the Piper Sandler 36th Annual Healthcare Conference

ZURA 11.25.2024

SERA-AI Powered Highlights
Drug:ZB-106 tibulizumab
Drug:ZB-168 crebankitug
Drug:ZB-880 torudokimab
Date of Upcoming Event:2024-12-03
Name of Upcoming Event:Piper Sandler 36th Annual Healthcare Conference
Full Press ReleaseSEC FilingsOur ZURA Tweets

About Gravity Analytica

Recent News

  • 12.23.2024 - Zura Bio Launches Global Phase 2 TibuSURE Study to Evaluate Tibulizumab in Adults With Systemic Sclerosis
  • 12.03.2024 - Piper Sandler 36th Annual Healthcare Conference
  • 11.25.2024 - Zura Bio to Present at the Piper Sandler 36th Annual Healthcare Conference

Recent Filings

  • 01.13.2025 - EX-99.1 EX-99.1
  • 01.13.2025 - 8-K Current report
  • 12.31.2024 - 4 Statement of changes in beneficial ownership of securities

HENDERSON, Nev.--(BUSINESS WIRE)--Nov. 25, 2024--Zura Bio Limited(Nasdaq: ZURA) (“Zura Bio”), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of its senior leadership team will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference onTuesday, December 3, 2024, at9:00 a.m. ET, and will host investor meetings inNew York, NY.

A live webcast and a replay of the presentation will be available on the “News & Events” page within the Investors section of the Zura Bio website. The presentation will be archived on the website for at least 30 days following the events.

ABOUT ZURA BIO

Zura Bio is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. Currently, Zura Bio is developing three assets which have completed Phase 1/1b studies. The company is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880), with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other novel indications with unmet needs.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241125900161/en/

Megan K. WeinshankHead of Corporate Affairsir@zurabio.com

Source:Zura Bio Limited

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com